Skip to main content
Premium Trial:

Request an Annual Quote

Thomson Reuters Invests In GenoSpace


NEW YORK (GenomeWeb) – GenoSpace has received an undisclosed financial investment from Thomson Reuters that it will use to expand its customer base in research, clinical development, laboratory medicine, and clinical care.

This is Thomson Reuters' first investment in the precision medicine informatics market. However, Thomson Reuters and GenoSpace have been collaborators since 2012. Last year, they teamed up to provide the bioinformatics resources needed to support PathGroup's cancer testing service.

"We are pleased to welcome Thomson Reuters as a strategic investor," John Quackenbush, GenoSpace's CEO said in a statement. "This investment represents not only their confidence in our team and our offerings, but also the vision both companies share for the future of information-driven precision medicine."

Launched in 2012, Mass.-based GenoSpace offers a platform for genomic and clinical data access, analysis, interpretation, and reporting that supports research scientists, pathologists, oncologists, clinical trial specialists, medical directors, and patients.